Tarceva-Avastin combo meets endpoint

Genentech (NYSE:DNA) said a DSMB recommended ending the Phase IIIb ATLAS trial for first-line treatment of non-small cell

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE